Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
R-107 Depression Study Results Published in Nature Medicine
Details : R-107 (ketamine) is an oral NMDA receptor negative allosteric modulator, small molecule drug candidate, which is being evaluated for the treatment of treatment-resistant depression.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 25, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Daré Bioscience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Douglas Pharmaceuticals Secures US licensing Deal to Treat High Grade Cervical Dysplasia
Details : Under the license agreement with Douglas, Dare will be responsible for advancing the development of R-131-2 (Lopinavir/Ritonavir) in the U.S. for the treatment for cervical intraepithelial neoplasia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 27, 2023
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Daré Bioscience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Clindamycin Phosphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Daré Bioscience
Deal Size : $7.0 million
Deal Type : Financing
Daré Bioscience Completes Previously Announced Equity Financing
Details : The net proceeds will be used the commercial launch of XACIATO (clindamycin phosphate) vaginal gel, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older.
Product Name : Xaciato
Product Type : Antibiotic
Upfront Cash : Undisclosed
May 09, 2023
Lead Product(s) : Clindamycin Phosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Daré Bioscience
Deal Size : $7.0 million
Deal Type : Financing
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Douglas Pharmaceuticals Announces Formation of Clinical Advisory Board for Lead Program R-107
Details : R-107, an oral extended-release dose of racemic ketamine being developed as add-on or monotherapy for treatment resistant depression (TRD). It has demonstrated a significant antidepressant effect with maintenance of response at 3 months, high compliance ...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 26, 2023
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Recipient : Upsher-Smith Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Upsher-Smith Launches Isotretinoin Capsules
Details : Upsher-Smith's product is AB2-rated to the branded product, Absorica® (isotretinoin) capsules. Isotretinoin capsules are a generic version of ABSORICA® indicated for the treatment of severe recalcitrant nodular acne.
Product Name : Isotretinoin-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 25, 2021
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Recipient : Upsher-Smith Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial Data Suggests Major Breakthrough in Treatment Resistant Depression
Details : R-107 (extended-release oral dose of ketamine) act as a blocks the NMDA receptor and it is investigated for the treatment of treatment resistant depression.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 15, 2021
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketoconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Novum Pharmaceutical Research Services | ACM Global Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
A Therapeutic Equivalence Study of Ketoconazole Cream 2%
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 18, 2019
Lead Product(s) : Ketoconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Novum Pharmaceutical Research Services | ACM Global Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
KEY SERVICES
Reset All
End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.
